Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has issued an update.
Lepu Biopharma Co., Ltd. reported a significant increase in revenue for the year ending December 31, 2024, driven by the commercialization of its Pucotenlimab Injection and licensing income from its CMG901 product. The company also made notable advancements in its ADC pipeline, with several products entering advanced stages of clinical trials and receiving regulatory approvals, which could enhance its market positioning and offer promising treatment options for cancer patients.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative oncology drugs. The company is involved in the production of antibody-drug conjugates (ADCs) and other targeted therapies, aiming to address unmet medical needs in cancer treatment.
YTD Price Performance: 19.47%
Average Trading Volume: 8,579,545
Technical Sentiment Signal: Hold
Current Market Cap: HK$5.35B
Find detailed analytics on 2157 stock on TipRanks’ Stock Analysis page.